CIK 0001398733 · Non-accelerated filer<br>Smaller reporting company
Aquestive Therapeutics, Inc.
Sign in to watch- Ticker
- AQST
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 208623253
- Phone
- 908-941-1900
- Business address
- 184 LIBERTY CORNER ROAD, SUITE 305, WARREN, NJ
- Former names
- MonoSol Rx, Inc.
- Open-market buys, last 90 days
- $99,331
- in 1 filing
- Open-market sales, last 90 days
- $378,930
- in 4 filings, $379K under 10b5-1 plans
Net −$279,599. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-02-28 | Kendall Keith J CEO and President | Option exercise · Restricted Stock Units | −14,572 | 72,860 | ||
| 2019-02-28 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +14,572 | 1,034,363 | ||
| 2019-02-28 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −6,721 | $8.05 | $54K | 1,027,642 |
| 2019-02-28 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise · Restricted Stock Units | −14,572 | 72,860 | ||
| 2019-01-02 | Slatko Gary H SVP, Chief Medical Officer | Grant or award · Stock Option (Right to Purchase) | +75,000 | 75,000 | ||
| 2018-12-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +329 | 1,019,953 | ||
| 2018-12-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −162 | $6.30 | $1K | 1,019,791 |
| 2018-12-31 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise · Restricted Stock Unit | −329 | 1,978 | ||
| 2018-12-31 | Kendall Keith J CEO and President | Option exercise | +329 | 628,863 | ||
| 2018-12-31 | Kendall Keith J CEO and President | Shares withheld for taxes | −162 | $6.30 | $1K | 628,701 |
| 2018-12-31 | Kendall Keith J CEO and President | Option exercise · Restricted Stock Unit | −329 | 1,978 | ||
| 2018-12-10 | Schobel Alexander Mark Chief Innovation/Tech Officer | Purchase | +1,000 | $7.78 | $8K | 1,019,624 |
| 2018-12-10 | Barber Daniel SVP-Chief Strategy/Dev Officer | Purchase | +1,000 | $8.00 | $8K | 99,959 |
| 2018-12-06 | Schobel Alexander Mark Chief Innovation/Tech Officer | Purchase | +2,000 | $8.69 | $17K | 1,018,624 |
| 2018-12-06 | Maxwell John T. SVP-Chief Financial Officer | Purchase | +5,000 | $8.87 | $44K | 153,614 |
| 2018-11-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise | +14,572 | 1,023,801 | ||
| 2018-11-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Shares withheld for taxes | −7,177 | $8.59 | $62K | 1,016,624 |
| 2018-11-30 | Schobel Alexander Mark Chief Innovation/Tech Officer | Option exercise · Restricted Stock Unit | −14,572 | 87,432 | ||
| 2018-11-30 | Kendall Keith J CEO and President | Option exercise | +14,572 | 635,711 | ||
| 2018-11-30 | Kendall Keith J CEO and President | Shares withheld for taxes | −7,177 | $8.59 | $62K | 628,534 |
Page 21 of 24 · 462 trades